Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stok Raporu

Piyasa değeri: US$412.3m

Esperion Therapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Esperion Therapeutics CEO'su Sheldon Koenig, May2021 tarihinde atandı, in görev süresi 3.5 yıldır. in toplam yıllık tazminatı $ 2.97M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.3% maaş ve 75.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.087% ine doğrudan sahiptir ve bu hisseler $ 359.77K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.7 yıl ve 3.3 yıldır.

Anahtar bilgiler

Sheldon Koenig

İcra Kurulu Başkanı

US$3.0m

Toplam tazminat

CEO maaş yüzdesi24.3%
CEO görev süresi3.5yrs
CEO sahipliği0.09%
Yönetim ortalama görev süresi2.7yrs
Yönetim Kurulu ortalama görev süresi3.3yrs

Son yönetim güncellemeleri

Recent updates

Esperion Therapeutics: Strategically Positioned To Grow

Aug 16

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

Jan 20

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Oct 27

Esperion: Hunting Big Game In The Danger Zone

Aug 05

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

May 09
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

CEO Tazminat Analizi

Sheldon Koenig'un ücretlendirmesi Esperion Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$98m

Mar 31 2024n/an/a

-US$87m

Dec 31 2023US$3mUS$721k

-US$209m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$222m

Mar 31 2023n/an/a

-US$239m

Dec 31 2022US$4mUS$683k

-US$234m

Sep 30 2022n/an/a

-US$243m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$8mUS$566k

-US$269m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$325m

Mar 31 2021n/an/a

-US$156m

Dec 31 2020US$508kUS$23k

-US$144m

Tazminat ve Piyasa: Sheldon 'ın toplam tazminatı ($USD 2.97M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.35M ).

Tazminat ve Kazançlar: Sheldon 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Sheldon Koenig (58 yo)

3.5yrs

Görev süresi

US$2,968,565

Tazminat

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sheldon Koenig
President3.5yrsUS$2.97m0.087%
$ 359.8k
Eric Warren
Chief Commercial Officer2.7yrsUS$1.08m0.083%
$ 341.5k
Benjamin Halladay
Chief Financial Officer2yrsVeri yok0.12%
$ 512.5k
Glenn Brame
Chief Technical Operations Officer1.8yrsVeri yokVeri yok
Benjamin Looker
General Counsel & Corporate Secretary2.8yrsUS$1.29m0.094%
$ 385.9k
Tiffany Aldrich
Associate Director of Corporate Communicationsno dataVeri yokVeri yok
Betty Swartz
Chief Business Officerno dataVeri yokVeri yok

2.7yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: ESPR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sheldon Koenig
President3.5yrsUS$2.97m0.087%
$ 359.8k
Nicole Vitullo
Lead Independent Director16.6yrsUS$94.78k0.016%
$ 66.8k
Alan Fuhrman
Independent Non-Employee Director4.7yrsUS$104.78k0.027%
$ 112.2k
Antonio Gotto
Independent Director10.8yrsUS$82.28k0.026%
$ 108.4k
Jay Shepard
Independent Director6.5yrsUS$97.28k0.026%
$ 108.4k
Stephen Rocamboli
Independent Director2.6yrsUS$94.78k0.018%
$ 76.2k
J. Carroll
Independent Chairperson2.4yrsUS$117.28k0.033%
$ 135.9k
Peter Libby
Member of Scientific Advisory Board2.3yrsVeri yokVeri yok
Seth H. Fischer
Independent Director3.1yrsUS$99.78k0.014%
$ 59.2k
Tracy Woody
Independent Director5.5yrsUS$91.97k0.014%
$ 59.7k
Erin Bohula
Member of Scientific Advisory Board2.3yrsVeri yokVeri yok
Jeffrey Bender
Member of Scientific Advisory Board2.3yrsVeri yokVeri yok

3.3yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ESPR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).